Compare Incyte Corporation (INCY) vs Unilever plc (UL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Unilever plc — how do they compare? Incyte Corporation trades at $120.94 (market cap $24.54B), while Unilever plc trades at $61.8 (market cap $134.06B). The key difference: Unilever plc is far larger — about 5.5× Incyte Corporation's market cap, and Unilever plc pays a 3.65% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| INCY | UL | |
|---|---|---|
Market Cap | $24.54B | $134.06B |
Sector | Health | Consumer Staples |
52-Week High | $129.93 | $74.59 |
52-Week Low | $81.61 | $55.05 |
Enterprise Value | $20.04B | $159.86B |
Dividend Yield | — | 3.65% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte Corporation (INCY) trades at $120.93, down 0.51% on the day, near its 52-week high. The stock shows strong fundamental momentum with Q2 2026 EPS beating estimates at $3.09 versus $2.15 expected, driven by robust Jakafi and Opzelura sales. Revenue growth accelerated to $5.14 billion in 2025, with net income margin expanding to 27.71%. Technical indicators signal a bullish trend with moving averages supporting upside, while oscillators remain neutral.
Outlook remains positive given raised 2026 revenue guidance and recent EU approval for Opzelura, though risks include competitive pressures and reliance on key products. Analyst consensus is bullish with a $122.82 price target, implying modest upside from current levels amid solid institutional ownership trends.
Unilever (UL) trades at $61.75, down 1.77% on the day, with a bearish technical signal. The stock shows strong profitability with a net income margin of 18.75% and ROE of 53.32%, but recent quarters have seen EPS misses against expectations. A major development is the planned $65 billion merger with McCormick's food business, expected to close in 2027, which could reshape growth prospects.
Outlook is mixed: robust cash flow and dividend yield near 1.75% support income investors, but execution risks on the McCormick deal and volatile earnings pose challenges. Analysts are divided, with 51% hold ratings, reflecting uncertainty amid strategic shifts. The stock appeals for its defensive staples exposure but requires monitoring of integration progress.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Unilever plc
Unilever is a diversified personal product (42% of 2021 sales by value), home care (20%), and packaged food (38%) company. Its brands include Knorr soups and sauces, Hellmann's mayonnaise, Lipton teas, Axe and Dove skin products, and the TRESemme haircare brand. The firm has been acquisitive in recent years
Read more on UL →
